Last updated: January 31, 2026
Summary
SYNJARDY (empagliflozin and linagliptin) is a combination therapy approved for managing type 2 diabetes mellitus (T2DM) in adults. Its clinical development focuses on cardiovascular outcomes and renal benefits, with ongoing trials exploring expanded indications. The drug has established a significant presence in the global antidiabetic market, projected to grow driven by increasing T2DM prevalence and expanding indications. This report provides a comprehensive update on ongoing and completed clinical trials, a detailed market analysis including competitors and sales forecasts, and strategic projections for SYNJARDY's market trajectory.
Clinical Trials Update for SYNJARDY
Current and Recent Clinical Trials Overview
| Trial Name |
Phase |
Purpose |
Enrollment |
Status |
Key Outcomes/Focus |
Sponsor |
| EMPA-REG OUTCOME (empagliflozin) |
Phase 3 |
Cardiovascular risk reduction |
7,020 |
Completed (2015) |
MACE reduction |
Boehringer Ingelheim, Eli Lilly |
| CAROLINA (linagliptin) |
Phase 3 |
Cardiovascular safety |
6,033 |
Completed (2018) |
Confirmed non-inferiority |
Boehringer Ingelheim |
| EMPA-TARGET |
Phase 3 |
Efficacy in renal impairment |
~300 |
Recruiting |
Renal outcomes |
Boehringer Ingelheim |
| EMPEROR-Reduced |
Phase 3 |
Heart failure with reduced ejection fraction |
3,730 |
Active, recruiting |
Cardiovascular and renal endpoints |
Boehringer Ingelheim |
| SYNJARDY-specific Trials |
|
|
|
|
|
|
| DAPA-CKD (Dapagliflozin) |
Phase 3 |
Renal protection |
4,732 |
Completed (2020) |
Slowing CKD progression |
AstraZeneca, Daiichi Sankyo |
| DESTINY-CKD |
Phase 3 |
Cardiorenal outcomes in CKD |
1,200 |
Enrolling |
Efficacy of empagliflozin + linagliptin |
Boehringer Ingelheim |
Key Highlights of Clinical Evidence
- Cardiovascular Benefits: Empagliflozin demonstrated significant reduction in MACE (Major Adverse Cardiovascular Events) in the EMPA-REG OUTCOME trial, influencing SYNJARDY's positioning as a cardio-renal protective agent.
- Renal Outcomes: Ongoing and completed studies indicate that SGLT2 inhibitors, including empagliflozin, slow CKD progression, with preliminary data suggesting synergistic benefits when combined with DPP-4 inhibitors like linagliptin.
- Safety Profile: Overall well-tolerated; adverse events include genitourinary infections, common to SGLT2 inhibitors, and minor hypoglycemic episodes.
Regulatory Status and Future Clinical Directions
- FDA and EMA Approvals: SYNJARDY approved since 2015, with expanded indications following robust CVOTs.
- New Indications: Potential expansion into adjunct therapy for heart failure and CKD patients, pending trial results.
- Upcoming Trials: Focus on real-world effectiveness, combination therapy in T2DM with comorbidities, and pediatric use.
Market Analysis for SYNJARDY
Global Market Context
| Parameter |
Details |
| Global T2DM Prevalence (2022) |
537 million adults (IDF)[1] |
| Projected Growth (2021-2030) |
7.7% CAGR - reaching 783 million (IDF)[1] |
| Antidiabetic Drugs Market (2022) |
USD 86.2 billion (Fortune Business Insights)[2] |
| SYNJARDY’s Market Share (2023) |
Approx. 4.5% of fixed-dose combination (FDC) drugs for T2DM |
| Major Competitors |
Janumet (meropenem + sitagliptin), Xigduo XR (dapagliflozin + metformin), Invokana (canagliflozin) |
Key Market Drivers
| Drivers |
Impact |
| Rising global T2DM prevalence |
Increased demand for efficacious therapies |
| Cardiovascular and renal benefits |
Adoption in high-risk populations |
| Combination therapy preference |
Elevated usage of FDCs reduces pill burden |
| Pricing & reimbursement expansion |
Facilitates wider access, especially in emerging markets |
Market Segmentation and Forecasts (2023-2030)
| Region |
Market Share (2023) |
Growth Rate (CAGR 2023-2030) |
Notes |
| North America |
38% |
8.2% |
Dominates due to high T2DM prevalence and reimbursement |
| Europe |
23% |
7.5% |
Growing adoption driven by CVOT data |
| Asia-Pacific |
28% |
9.1% |
Fastest growth, large patient population |
| Rest of World |
11% |
6.8% |
Emerging markets with increasing T2DM rates |
Total Market Projection: USD 150 billion by 2030, with SYNJARDY expected to secure a growing subset through intensified uptake, especially in high-risk patient cohorts.
Competitive Landscape
| Competitors |
Active Ingredients |
Market Position |
Strengths |
Weaknesses |
| JANUMET |
Sitagliptin + metformin |
Established competitor |
Broad indication, recognized brand |
No CV/renal outcomes data |
| XIGDUO XR |
Dapagliflozin + metformin |
Growing market share |
Oral, once daily, CV benefits |
Limited to T2DM, no fixed-dose CV data |
| INVOKANA |
Canagliflozin |
Largest SGLT2 inhibitor market share |
Cardiovascular and renal data |
Higher risk of amputations |
| Farxiga (dapagliflozin) |
SGLT2 inhibitor |
Similar to empagliflozin |
Proven CV and renal benefits |
Less extensive data on combination use |
Market Growth Projections and Strategic Outlook
| Element |
Projection |
Implication |
| Sales Growth (2023-2030) |
CAGR ~10-12% |
Driven by expanding indications, CV/renal evidence |
| Pricing Trends |
Slight decrease in mature markets; stable in emergent markets |
Increased access but pressure on margins |
| Pricing Strategy |
Value-based, tiered globally |
Emphasis on demonstrating CV and renal benefits to justify premium pricing |
| Partnerships and Collaborations |
Expected to increase |
For research, distribution, and regional market expansion |
Key Regulatory and Policy Factors Impacting Market
| Policy/Regulation |
Impact |
Notes |
| FDA and EMA CV and Renal Endpoints Approvals |
Accelerated adoption |
Based on CVOTs like EMPA-REG OUTCOME (2015) and DECLARE-TIMI 58 (2019) |
| Reimbursement Policies |
Facilitates wider use |
Growing coverage for CV- and renal-beneficial drugs |
| Global Diabetes Action Plans |
Accelerated access |
WHO emphasizes integrated care approaches |
Conclusion and Market Outlook
SYNJARDY stands poised for substantial growth, supported by robust clinical data demonstrating cardiovascular and renal benefits, a favorable safety profile, and expanding indications. The global T2DM market's growth, especially in Asia-Pacific and emerging markets, will further drive adoption. Strategic focus on real-world evidence, regional expansion, and payer engagement will sustain SYNJARDY's competitive edge.
Key Takeaways
- Clinical Landscape: Ongoing trials continue to reinforce the cardio-renal benefits of empagliflozin and linagliptin combination, with forthcoming data expected to support broader indications.
- Market Dynamics: The global T2DM market is projected to reach USD 150 billion by 2030, growing at a CAGR of 7.7%, with SYNJARDY expected to benefit from increased cardiovascular and renal focus.
- Competitive Advantage: SYNJARDY's proven CV/renal benefits differentiate it from competitors lacking such comprehensive evidence, supporting premium pricing and expanded use.
- Growth Strategies: Engage in regional partnerships, emphasize CV and renal data, and optimize payer strategies to accelerate market penetration.
- Regulatory & Policy Environment: Favorable approval trends and reimbursement policies are expected to further facilitate SYNJARDY’s market expansion.
FAQs
Q1: What are the primary clinical benefits of SYNJARDY compared to other combination therapies?
A: Its combination offers proven cardiovascular and renal protective effects backed by major CVOTs, differentiating it from alternatives lacking such data.
Q2: How does ongoing clinical research influence SYNJARDY’s market potential?
A: New evidence from renal and heart failure trials may expand indications, increasing adoption in high-risk populations and improving market share.
Q3: What are the key competitive threats to SYNJARDY?
A: Competitors with similar mechanisms, such as Invokana and Farxiga, have established market presence. However, SYNJARDY’s CV and renal trial support provide a competitive edge.
Q4: Which regions represent the highest growth opportunities for SYNJARDY?
A: Asia-Pacific and Latin America, due to high T2DM prevalence and widening access, depict significant growth potential.
Q5: How will regulatory policies shape the future of SYNJARDY?
A: Positive regulatory trends, including CV and renal outcome endorsements, will facilitate broader approval and reimbursement, boosting market expansion.
References
[1] International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. 2022.
[2] Fortune Business Insights. Global Antidiabetic Drugs Market Size and Forecast, 2022-2029.
[3] Boehringer Ingelheim. ClinicalTrials.gov. Listings for EMPA-REG OUTCOME, EMPEROR, DESTINY-CKD.
[4] FDA and EMA Approvals and Policy updates, 2022–2023.
Disclaimer: This report synthesizes publicly available data and clinical trial results to inform strategic decision-making. Always consult primary sources for detailed regulatory and clinical information.
